Silencing of the IKKε gene by siRNA inhibits invasiveness and growth of breast cancer cells

Breast Cancer Research

Volumn 12, Issue 5, 2010, Pages

  Qin, Bin ^a   Cheng, Kun ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLIN D1; DOXORUBICIN; I KAPPA B KINASE EPSILON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PROTEIN BCL 2; SMALL INTERFERING RNA; I KAPPA B KINASE;

ANCHORAGE INDEPENDENT GROWTH; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CLONOGENESIS; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; I KAPPA B KINASE EPSILON GENE; NUCLEOTIDE SEQUENCE; ONCOGENE; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; WESTERN BLOTTING; BIOSYNTHESIS; BREAST TUMOR; CANCER INVASION; CELL CYCLE CHECKPOINT; CELL MOTION; DOWN REGULATION; FEMALE; GENETICS; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYCLIN D1; DOWN-REGULATION; FEMALE; HUMANS; I-KAPPA B KINASE; NEOPLASM INVASIVENESS; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 78650866392     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2644     Document Type: Article

References (41)

1. Chau TL, Gioia R, Gatot JS, Patrascu F, Carpentier I, Chapelle JP, O'Neill L, Beyaert R, Piette J, Chariot A. Are the IKKs and IKK-related kinases TBK1 and IKK-epsilon similarly activated?. Trends Biochem Sci 2008, 33:171-180. 10.1016/j.tibs.2008.01.002, 18353649.
2. Kishore N, Huynh QK, Mathialagan S, Hall T, Rouw S, Creely D, Lange G, Caroll J, Reitz B, Donnelly A, Boddupalli H, Combs RG, Kretzmer K, Tripp CS. IKK-i and TBK-1 are enzymatically distinct from the homologous enzyme IKK-2: comparative analysis of recombinant human IKK-i, TBK-1, and IKK-2. J Biol Chem 2002, 277:13840-13847. 10.1074/jbc.M110474200, 11839743.
3. Sethi G, Sung B, Aggarwal BB. Nuclear factor-κB activation: from bench to bedside. Exp Biol Med (Maywood) 2008, 233:21-31. 10.3181/0707-MR-196, 18156302.
4. Adli M, Baldwin AS. IKK-i/IKKε controls constitutive, cancer cell-associated NF-κB activity via regulation of Ser-536 p65/RelA phosphorylation. J Biol Chem 2006, 281:26976-26984. 10.1074/jbc.M603133200, 16840782.
5. Peters RT, Liao SM, Maniatis T. IKKε is part of a novel PMA-inducible IκB kinase complex. Mol Cell 2000, 5:513-522. 10.1016/S1097-2765(00)80445-1, 10882136.
6. Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, Dunn IF, Sjostrom SK, Garraway LA, Weremowicz S, Richardson AL, Greulich H, Stewart CJ, Mulvey LA, Shen RR, Ambrogio L, Hirozane-Kishikawa T, Hill DE, Vidal M, Meyerson M, Grenier JK, Hinkle G, Root DE, Roberts TM, Lander ES, Polyak K, Hahn WC. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 2007, 129:1065-1079. 10.1016/j.cell.2007.03.052, 17574021.
7. Hutti JE, Shen RR, Abbott DW, Zhou AY, Sprott KM, Asara JM, Hahn WC, Cantley LC. Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKε promotes cell transformation. Mol Cell 2009, 34:461-472. 10.1016/j.molcel.2009.04.031, 2746958, 19481526.
8. Kravchenko VV, Mathison JC, Schwamborn K, Mercurio F, Ulevitch RJ. IKKi/IKKε plays a key role in integrating signals induced by pro-inflammatory stimuli. J Biol Chem 2003, 278:26612-26619. 10.1074/jbc.M303001200, 12736252.
9. Tenoever BR, Ng SL, Chua MA, McWhirter SM, Garcia-Sastre A, Maniatis T. Multiple functions of the IKK-related kinase IKKε in interferon-mediated antiviral immunity. Science 2007, 315:1274-1278. 10.1126/science.1136567, 17332413.
10. Peant B, Diallo JS, Dufour F, Le Page C, Delvoye N, Saad F, Mes-Masson AM. Over-expression of IκB-kinase-epsilon (IKKε/IKKi) induces secretion of inflammatory cytokines in prostate cancer cell lines. Prostate 2009, 69:706-718. 10.1002/pros.20912, 19170126.
11. Eddy SF, Guo S, Demicco EG, Romieu-Mourez R, Landesman-Bollag E, Seldin DC, Sonenshein GE. Inducible IκB kinase/IκB kinase epsilon expression is induced by CK2 and promotes aberrant nuclear factor-κB activation in breast cancer cells. Cancer Res 2005, 65:11375-11383. 10.1158/0008-5472.CAN-05-1602, 16357145.
12. Sithanandam G, Fornwald LW, Fields J, Anderson LM. Inactivation of ErbB3 by siRNA promotes apoptosis and attenuates growth and invasiveness of human lung adenocarcinoma cell line A549. Oncogene 2005, 24:1847-1859. 10.1038/sj.onc.1208381, 15688028.
13. Liu TG, Yin JQ, Shang BY, Min Z, He HW, Jiang JM, Chen F, Zhen YS, Shao RG. Silencing of hdm2 oncogene by siRNA inhibits p53-dependent human breast cancer. Cancer Gene Ther 2004, 11:748-756. 10.1038/sj.cgt.7700753, 15375377.
14. Cheng K, Yang N, Mahato RI. TGF-beta1 gene silencing for treating liver fibrosis. Mol Pharm 2009, 6:772-779. 10.1021/mp9000469, 2743970, 19388665.
15. Cheng K, Fraga D, Zhang C, Kotb M, Gaber AO, Guntaka RV, Mahato RI. Adenovirus-based vascular endothelial growth factor gene delivery to human pancreatic islets. Gene Ther 2004, 11:1105-1116. 10.1038/sj.gt.3302267, 15238996.
16. TScratch. , http://www.cse-lab.ethz.ch/index.php?&option=com_content&view=article&id=363
17. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007, 449:682-688. 10.1038/nature06174, 17898713.
18. Tiang JM, Butcher NJ, Minchin RF. Small molecule inhibition of arylamine N-acetyltransferase type I inhibits proliferation and invasiveness of MDA-MB-231 breast cancer cells. Biochem Biophys Res Commun 2010, 393:95-100. 10.1016/j.bbrc.2010.01.087, 20100460.
19. Pearson G, English JM, White MA, Cobb MH. ERK5 and ERK2 cooperate to regulate NF-κB and cell transformation. J Biol Chem 2001, 276:7927-7931. 10.1074/jbc.M009764200, 11118448.
20. Imoto M, Doki Y, Jiang W, Han EK, Weinstein IB. Effects of cyclin D1 overexpression on G1 progression-related events. Exp Cell Res 1997, 236:173-180. 10.1006/excr.1997.3713, 9344597.
21. Musgrove EA, Lee CS, Buckley MF, Sutherland RL. Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc Natl Acad Sci USA 1994, 91:8022-8026. 10.1073/pnas.91.17.8022, 44537, 8058751.
22. Tapia MA, Gonzalez-Navarrete I, Dalmases A, Bosch M, Rodriguez-Fanjul V, Rolfe M, Ross JS, Mezquita J, Mezquita C, Bachs O, Gascon P, Rojo F, Perona R, Rovira A, Albanell J. Inhibition of the canonical IKK/NFκB pathway sensitizes human cancer cells to doxorubicin. Cell Cycle 2007, 6:2284-2292. 10.4161/cc.6.18.4721, 17890907.
23. Guo JP, Shu SK, He L, Lee YC, Kruk PA, Grenman S, Nicosia SV, Mor G, Schell MJ, Coppola D, Cheng JQ. Deregulation of IKBKE is associated with tumor progression, poor prognosis, and cisplatin resistance in ovarian cancer. Am J Pathol 2009, 175:324-333. 10.2353/ajpath.2009.080767, 2708818, 19497997.
24. Renner F, Moreno R, Schmitz ML. SUMOylation-dependent localization of IKKε in PML nuclear bodies is essential for protection against DNA-damage-triggered cell death. Mol Cell 2010, 37:503-515. 10.1016/j.molcel.2010.01.018, 20188669.
25. Basseres DS, Baldwin AS. Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression. Oncogene 2006, 25:6817-6830. 10.1038/sj.onc.1209942, 17072330.
26. Sung B, Pandey MK, Nakajima Y, Nishida H, Konishi T, Chaturvedi MM, Aggarwal BB. Identification of a novel blocker of IκBα kinase activation that enhances apoptosis and inhibits proliferation and invasion by suppressing nuclear factor-κB. Mol Cancer Ther 2008, 7:191-201. 10.1158/1535-7163.MCT-07-0406, 18202022.
27. Lee TK, Poon RT, Wo JY, Ma S, Guan XY, Myers JN, Altevogt P, Yuen AP. Lupeol suppresses cisplatin-induced nuclear factor-κB activation in head and neck squamous cell carcinoma and inhibits local invasion and nodal metastasis in an orthotopic nude mouse model. Cancer Res 2007, 67:8800-8809. 10.1158/0008-5472.CAN-07-0801, 17875721.
28. Luo JL, Tan W, Ricono JM, Korchynskyi O, Zhang M, Gonias SL, Cheresh DA, Karin M. Nuclear cytokine-activated IKKα controls prostate cancer metastasis by repressing Maspin. Nature 2007, 446:690-694. 10.1038/nature05656, 17377533.
29. MacKeigan JP, Murphy LO, Blenis J. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat Cell Biol 2005, 7:591-600. 10.1038/ncb1258, 15864305.
30. Desagher S, Martinou JC. Mitochondria as the central control point of apoptosis. Trends Cell Biol 2000, 10:369-377. 10.1016/S0962-8924(00)01803-1, 10932094.
31. Ferlini C, Raspaglio G, Mozzetti S, Distefano M, Filippetti F, Martinelli E, Ferrandina G, Gallo D, Ranelletti FO, Scambia G. Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance. Mol Pharmacol 2003, 64:51-58. 10.1124/mol.64.1.51, 12815160.
32. Tophkhane C, Yang S, Bales W, Archer L, Osunkoya A, Thor AD, Yang X. Bcl-2 overexpression sensitizes MCF-7 cells to genistein by multiple mechanisms. Int J Oncol 2007, 31:867-874.
33. Buchholz TA, Garg AK, Chakravarti N, Aggarwal BB, Esteva FJ, Kuerer HM, Singletary SE, Hortobagyi GN, Pusztai L, Cristofanilli M, Sahin AA. The nuclear transcription factor κB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer. Clin Cancer Res 2005, 11:8398-8402. 10.1158/1078-0432.CCR-05-0885, 16322301.
34. Emi M, Kim R, Tanabe K, Uchida Y, Toge T. Targeted therapy against Bcl-2-related proteins in breast cancer cells. Breast Cancer Res 2005, 7:R940-R952. 10.1186/bcr1323, 1410745, 16280040.
35. Julien T, Frankel B, Longo S, Kyle M, Gibson S, Shillitoe E, Ryken T. Antisense-mediated inhibition of the bcl-2 gene induces apoptosis in human malignant glioma. Surg Neurol 2000, 53:360-368. discussion 368-369, 10.1016/S0090-3019(00)00178-6, 10825522.
36. Lima RT, Martins LM, Guimaraes JE, Sambade C, Vasconcelos MH. Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells. Cancer Gene Ther 2004, 11:309-316. 10.1038/sj.cgt.7700706, 15031723.
37. Akar U, Chaves-Reyez A, Barria M, Tari A, Sanguino A, Kondo Y, Kondo S, Arun B, Lopez-Berestein G, Ozpolat B. Silencing of Bcl-2 expression by small interfering RNA induces autophagic cell death in MCF-7 breast cancer cells. Autophagy 2008, 4:669-679.
38. Hsu SY, Kaipia A, McGee E, Lomeli M, Hsueh AJ. Bok is a pro-apoptotic Bcl-2 protein with restricted expression in reproductive tissues and heterodimerizes with selective anti-apoptotic Bcl-2 family members. Proc Natl Acad Sci USA 1997, 94:12401-12406. 10.1073/pnas.94.23.12401, 24966, 9356461.
39. Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C, Barnes D, Peters G. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 1994, 54:1812-1817.
40. Roy PG, Thompson AM. Cyclin D1 and breast cancer. Breast 2006, 15:718-727. 10.1016/j.breast.2006.02.005, 16675218.
41. Guo JP, Shu SK, Esposito NN, Coppola D, Koomen JM, Cheng JQ. IKKε phosphorylation of estrogen receptor alpha Ser-167 and contribution to tamoxifen resistance in breast cancer. J Biol Chem 2010, 285:3676-3684. 10.1074/jbc.M109.078212, 19940156.